| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hemangioma, Cavernous, Central Nervous System | 74 | 2024 | 223 | 20.710 |
Why?
|
| Cerebral Hemorrhage | 84 | 2024 | 325 | 12.310 |
Why?
|
| Intracranial Arteriovenous Malformations | 48 | 2014 | 104 | 5.430 |
Why?
|
| Brain Neoplasms | 35 | 2022 | 763 | 5.040 |
Why?
|
| Tissue Plasminogen Activator | 26 | 2024 | 162 | 4.640 |
Why?
|
| Fibrinolytic Agents | 24 | 2024 | 202 | 4.230 |
Why?
|
| Hemangioma, Cavernous | 24 | 2021 | 69 | 4.000 |
Why?
|
| Thrombolytic Therapy | 17 | 2023 | 220 | 3.780 |
Why?
|
| Intracranial Hemorrhages | 15 | 2024 | 120 | 2.710 |
Why?
|
| Magnetic Resonance Imaging | 67 | 2023 | 3362 | 2.640 |
Why?
|
| Minimally Invasive Surgical Procedures | 18 | 2023 | 237 | 2.610 |
Why?
|
| Intracranial Aneurysm | 28 | 2012 | 158 | 2.390 |
Why?
|
| Neurosurgical Procedures | 16 | 2021 | 213 | 2.200 |
Why?
|
| Capillary Permeability | 6 | 2021 | 130 | 2.120 |
Why?
|
| Cerebral Ventricles | 11 | 2018 | 76 | 2.100 |
Why?
|
| Humans | 302 | 2024 | 86643 | 1.980 |
Why?
|
| Apoptosis Regulatory Proteins | 17 | 2023 | 199 | 1.980 |
Why?
|
| rho-Associated Kinases | 12 | 2019 | 159 | 1.900 |
Why?
|
| Proto-Oncogene Proteins | 18 | 2023 | 645 | 1.840 |
Why?
|
| Hemorrhage | 10 | 2023 | 268 | 1.810 |
Why?
|
| Drainage | 13 | 2022 | 157 | 1.770 |
Why?
|
| Hematoma | 12 | 2024 | 104 | 1.770 |
Why?
|
| Central Nervous System Vascular Malformations | 8 | 2023 | 32 | 1.770 |
Why?
|
| Biomarkers | 18 | 2023 | 1718 | 1.730 |
Why?
|
| Stroke | 20 | 2024 | 965 | 1.720 |
Why?
|
| Brain | 40 | 2021 | 2216 | 1.690 |
Why?
|
| Central Nervous System Neoplasms | 6 | 2019 | 81 | 1.680 |
Why?
|
| Disease Models, Animal | 18 | 2021 | 2232 | 1.590 |
Why?
|
| Male | 158 | 2024 | 40965 | 1.550 |
Why?
|
| KRIT1 Protein | 23 | 2023 | 62 | 1.500 |
Why?
|
| Female | 163 | 2024 | 44532 | 1.490 |
Why?
|
| Epilepsy | 16 | 2020 | 397 | 1.410 |
Why?
|
| Middle Aged | 118 | 2024 | 25028 | 1.390 |
Why?
|
| Neurosurgery | 10 | 2011 | 84 | 1.320 |
Why?
|
| Adult | 113 | 2023 | 25648 | 1.310 |
Why?
|
| Microtubule-Associated Proteins | 14 | 2022 | 176 | 1.240 |
Why?
|
| 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 6 | 2020 | 36 | 1.240 |
Why?
|
| Treatment Outcome | 50 | 2024 | 7993 | 1.230 |
Why?
|
| Cerebral Intraventricular Hemorrhage | 5 | 2021 | 9 | 1.230 |
Why?
|
| Carotid Artery Diseases | 12 | 2011 | 97 | 1.160 |
Why?
|
| Vascular Endothelial Growth Factor A | 7 | 2024 | 407 | 1.140 |
Why?
|
| Intensive Care Units | 3 | 2023 | 373 | 1.130 |
Why?
|
| Aged | 81 | 2023 | 18415 | 1.090 |
Why?
|
| Clinical Trials as Topic | 9 | 2023 | 1169 | 1.090 |
Why?
|
| Subarachnoid Hemorrhage | 12 | 2018 | 137 | 1.050 |
Why?
|
| Propranolol | 2 | 2022 | 45 | 0.990 |
Why?
|
| Cerebrovascular Disorders | 12 | 2004 | 143 | 0.990 |
Why?
|
| Iron | 5 | 2018 | 164 | 0.940 |
Why?
|
| B-Lymphocytes | 5 | 2018 | 724 | 0.890 |
Why?
|
| Laser Therapy | 2 | 2021 | 142 | 0.890 |
Why?
|
| Cerebral Angiography | 29 | 2017 | 196 | 0.870 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 5 | 2019 | 379 | 0.870 |
Why?
|
| Adolescent | 48 | 2020 | 8981 | 0.870 |
Why?
|
| Endothelial Cells | 16 | 2024 | 428 | 0.850 |
Why?
|
| Brain Ischemia | 15 | 2023 | 398 | 0.850 |
Why?
|
| Membrane Proteins | 8 | 2021 | 1196 | 0.850 |
Why?
|
| Carotid Artery, Internal | 11 | 2011 | 69 | 0.820 |
Why?
|
| Catheterization | 6 | 2012 | 232 | 0.810 |
Why?
|
| Neovascularization, Pathologic | 8 | 2021 | 353 | 0.810 |
Why?
|
| Craniotomy | 6 | 2021 | 88 | 0.800 |
Why?
|
| Image Processing, Computer-Assisted | 7 | 2020 | 1204 | 0.800 |
Why?
|
| Socioeconomic Factors | 2 | 2023 | 567 | 0.790 |
Why?
|
| Adrenergic beta-1 Receptor Antagonists | 1 | 2021 | 9 | 0.790 |
Why?
|
| Tomography, X-Ray Computed | 39 | 2022 | 2601 | 0.780 |
Why?
|
| Young Adult | 21 | 2021 | 5976 | 0.780 |
Why?
|
| Mutation | 16 | 2023 | 3968 | 0.770 |
Why?
|
| Intracranial Hemorrhage, Hypertensive | 3 | 2019 | 5 | 0.740 |
Why?
|
| Prospective Studies | 16 | 2023 | 4213 | 0.730 |
Why?
|
| Aneurysm, Ruptured | 5 | 2012 | 51 | 0.730 |
Why?
|
| Arteriovenous Malformations | 6 | 2023 | 41 | 0.690 |
Why?
|
| Root Cause Analysis | 1 | 2018 | 3 | 0.680 |
Why?
|
| Mice | 25 | 2023 | 11352 | 0.670 |
Why?
|
| Cerebrovascular Circulation | 8 | 2021 | 212 | 0.660 |
Why?
|
| Seizures | 8 | 2020 | 297 | 0.660 |
Why?
|
| Transcriptome | 6 | 2024 | 580 | 0.650 |
Why?
|
| Child | 33 | 2020 | 6927 | 0.650 |
Why?
|
| Postoperative Complications | 17 | 2012 | 2207 | 0.640 |
Why?
|
| Thrombophilia | 1 | 2017 | 22 | 0.620 |
Why?
|
| Brain Mapping | 11 | 2016 | 548 | 0.620 |
Why?
|
| Risk Assessment | 11 | 2021 | 2261 | 0.610 |
Why?
|
| Simvastatin | 2 | 2019 | 106 | 0.600 |
Why?
|
| Endothelium, Vascular | 12 | 2020 | 435 | 0.600 |
Why?
|
| X-Ray Microtomography | 2 | 2019 | 80 | 0.590 |
Why?
|
| Embolization, Therapeutic | 9 | 2011 | 238 | 0.590 |
Why?
|
| Critical Care | 5 | 2013 | 370 | 0.590 |
Why?
|
| Thromboembolism | 1 | 2017 | 119 | 0.590 |
Why?
|
| Cerebral Veins | 9 | 2021 | 30 | 0.580 |
Why?
|
| Cytokines | 2 | 2017 | 776 | 0.580 |
Why?
|
| Animals | 39 | 2023 | 26582 | 0.570 |
Why?
|
| Cohort Studies | 16 | 2021 | 2767 | 0.550 |
Why?
|
| Child, Preschool | 17 | 2020 | 3612 | 0.540 |
Why?
|
| Carrier Proteins | 9 | 2019 | 673 | 0.540 |
Why?
|
| Cholesterol, HDL | 1 | 2016 | 165 | 0.520 |
Why?
|
| Prognosis | 20 | 2023 | 3679 | 0.510 |
Why?
|
| Follow-Up Studies | 23 | 2023 | 3640 | 0.490 |
Why?
|
| Stereotaxic Techniques | 7 | 2008 | 69 | 0.480 |
Why?
|
| Temporal Lobe | 15 | 2003 | 172 | 0.480 |
Why?
|
| Antigen-Antibody Complex | 1 | 2014 | 87 | 0.480 |
Why?
|
| Brain Diseases | 7 | 2001 | 180 | 0.480 |
Why?
|
| Genetic Predisposition to Disease | 9 | 2021 | 2271 | 0.480 |
Why?
|
| Risk Factors | 20 | 2022 | 5417 | 0.480 |
Why?
|
| Early Detection of Cancer | 1 | 2017 | 394 | 0.470 |
Why?
|
| Vitamin D | 1 | 2016 | 261 | 0.460 |
Why?
|
| Enzyme Inhibitors | 2 | 2019 | 639 | 0.460 |
Why?
|
| Mice, Transgenic | 7 | 2019 | 1540 | 0.450 |
Why?
|
| Combined Modality Therapy | 8 | 2019 | 1686 | 0.450 |
Why?
|
| Telangiectasia, Hereditary Hemorrhagic | 6 | 2023 | 15 | 0.440 |
Why?
|
| Clinical Trials, Phase III as Topic | 4 | 2021 | 172 | 0.440 |
Why?
|
| Reproducibility of Results | 12 | 2022 | 2705 | 0.430 |
Why?
|
| Mechanical Thrombolysis | 1 | 2012 | 15 | 0.430 |
Why?
|
| Intracranial Pressure | 9 | 2020 | 77 | 0.430 |
Why?
|
| Hemangioma | 6 | 1994 | 60 | 0.430 |
Why?
|
| Spinal Cord Neoplasms | 2 | 2004 | 48 | 0.420 |
Why?
|
| Aged, 80 and over | 19 | 2023 | 6509 | 0.410 |
Why?
|
| Hydrocephalus | 3 | 2022 | 101 | 0.410 |
Why?
|
| Elective Surgical Procedures | 1 | 2013 | 116 | 0.410 |
Why?
|
| Postoperative Care | 1 | 2013 | 221 | 0.410 |
Why?
|
| Vascular Surgical Procedures | 4 | 2020 | 148 | 0.410 |
Why?
|
| Aneurysm | 1 | 2011 | 58 | 0.400 |
Why?
|
| Choroid Plexus | 1 | 2011 | 14 | 0.400 |
Why?
|
| Cerebral Cortex | 9 | 2020 | 584 | 0.400 |
Why?
|
| Electroencephalography | 12 | 1999 | 709 | 0.390 |
Why?
|
| Zebrafish Proteins | 3 | 2021 | 144 | 0.390 |
Why?
|
| Knowledge | 2 | 2009 | 29 | 0.390 |
Why?
|
| Observer Variation | 6 | 2016 | 602 | 0.390 |
Why?
|
| Leukocytes | 4 | 2021 | 202 | 0.390 |
Why?
|
| Vasodilator Agents | 1 | 2011 | 152 | 0.390 |
Why?
|
| Gene Expression | 5 | 2004 | 1284 | 0.390 |
Why?
|
| Protein Kinase Inhibitors | 4 | 2019 | 589 | 0.380 |
Why?
|
| Mice, Knockout | 8 | 2021 | 1924 | 0.380 |
Why?
|
| Disease Progression | 8 | 2021 | 1531 | 0.380 |
Why?
|
| Cavernous Sinus | 6 | 2001 | 15 | 0.380 |
Why?
|
| Hodgkin Disease | 1 | 2012 | 177 | 0.380 |
Why?
|
| Longitudinal Studies | 5 | 2021 | 1019 | 0.370 |
Why?
|
| Catheters | 3 | 2023 | 74 | 0.370 |
Why?
|
| Biomedical Research | 2 | 2019 | 376 | 0.360 |
Why?
|
| Retrospective Studies | 20 | 2023 | 8489 | 0.360 |
Why?
|
| Blood Vessel Prosthesis | 2 | 2008 | 228 | 0.360 |
Why?
|
| Intracranial Hypertension | 3 | 2019 | 48 | 0.360 |
Why?
|
| Hypertension | 3 | 2022 | 1141 | 0.360 |
Why?
|
| Radiotherapy | 1 | 2012 | 328 | 0.360 |
Why?
|
| Kruppel-Like Transcription Factors | 6 | 2021 | 93 | 0.360 |
Why?
|
| Cerebral Arteries | 10 | 2009 | 74 | 0.360 |
Why?
|
| Time Factors | 11 | 2021 | 5210 | 0.350 |
Why?
|
| Chromosomes, Human, Pair 7 | 4 | 1998 | 79 | 0.350 |
Why?
|
| Chemistry | 1 | 2008 | 54 | 0.340 |
Why?
|
| Biological Science Disciplines | 1 | 2008 | 12 | 0.340 |
Why?
|
| Nobel Prize | 1 | 2008 | 10 | 0.340 |
Why?
|
| Science | 1 | 2009 | 34 | 0.340 |
Why?
|
| Cerebral Revascularization | 7 | 2008 | 26 | 0.340 |
Why?
|
| Plasma Cells | 3 | 2020 | 80 | 0.340 |
Why?
|
| Severity of Illness Index | 11 | 2017 | 1801 | 0.340 |
Why?
|
| Muscle, Smooth, Vascular | 5 | 2008 | 231 | 0.330 |
Why?
|
| Cerebrospinal Fluid Shunts | 3 | 2023 | 48 | 0.330 |
Why?
|
| Ischemic Attack, Transient | 9 | 2003 | 181 | 0.330 |
Why?
|
| Motor Cortex | 3 | 2001 | 195 | 0.330 |
Why?
|
| Intracranial Arteriosclerosis | 4 | 2023 | 49 | 0.330 |
Why?
|
| Oligoclonal Bands | 1 | 2007 | 5 | 0.320 |
Why?
|
| Nervous System Diseases | 5 | 1992 | 151 | 0.320 |
Why?
|
| Double-Blind Method | 8 | 2021 | 1823 | 0.320 |
Why?
|
| Brain Stem | 4 | 2021 | 165 | 0.320 |
Why?
|
| Ventriculostomy | 3 | 2018 | 26 | 0.320 |
Why?
|
| Green Fluorescent Proteins | 1 | 2008 | 305 | 0.310 |
Why?
|
| Signal Transduction | 10 | 2021 | 3241 | 0.310 |
Why?
|
| Magnetic Resonance Spectroscopy | 6 | 2019 | 318 | 0.310 |
Why?
|
| Tissue Scaffolds | 1 | 2008 | 106 | 0.310 |
Why?
|
| Surgical Instruments | 3 | 2011 | 57 | 0.310 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 3 | 2002 | 44 | 0.300 |
Why?
|
| Microscopy, Fluorescence | 1 | 2008 | 425 | 0.300 |
Why?
|
| Neurologic Examination | 7 | 2005 | 118 | 0.300 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2020 | 865 | 0.300 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2007 | 66 | 0.300 |
Why?
|
| Immunoglobulin G | 1 | 2009 | 456 | 0.290 |
Why?
|
| Image Enhancement | 1 | 2010 | 563 | 0.290 |
Why?
|
| Muscle Proteins | 3 | 2021 | 132 | 0.290 |
Why?
|
| Neoplasms | 3 | 2021 | 2898 | 0.290 |
Why?
|
| MAP Kinase Kinase Kinase 3 | 4 | 2021 | 12 | 0.290 |
Why?
|
| Epilepsy, Temporal Lobe | 9 | 2020 | 122 | 0.280 |
Why?
|
| Monitoring, Physiologic | 5 | 2020 | 268 | 0.280 |
Why?
|
| Acute Disease | 7 | 2020 | 826 | 0.280 |
Why?
|
| Carotid Arteries | 4 | 2000 | 127 | 0.270 |
Why?
|
| Survivors | 3 | 2022 | 226 | 0.270 |
Why?
|
| Gene Expression Profiling | 4 | 2024 | 1384 | 0.270 |
Why?
|
| Phenotype | 9 | 2021 | 2378 | 0.270 |
Why?
|
| Genotype | 7 | 2021 | 1851 | 0.260 |
Why?
|
| RNA, Messenger | 4 | 2021 | 1981 | 0.260 |
Why?
|
| Radiosurgery | 6 | 2009 | 272 | 0.260 |
Why?
|
| Coronary Artery Disease | 2 | 2007 | 350 | 0.260 |
Why?
|
| Sensitivity and Specificity | 10 | 2021 | 1991 | 0.260 |
Why?
|
| Patient Selection | 4 | 2023 | 685 | 0.260 |
Why?
|
| Extracellular Matrix Proteins | 3 | 2001 | 123 | 0.260 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 2 | 2023 | 56 | 0.250 |
Why?
|
| Brain Edema | 3 | 2013 | 50 | 0.250 |
Why?
|
| Feasibility Studies | 3 | 2021 | 751 | 0.250 |
Why?
|
| Contrast Media | 4 | 2021 | 1078 | 0.250 |
Why?
|
| Receptors, Cell Surface | 3 | 2018 | 286 | 0.250 |
Why?
|
| Epilepsies, Partial | 4 | 1991 | 42 | 0.250 |
Why?
|
| Machine Learning | 3 | 2021 | 232 | 0.250 |
Why?
|
| Gastrointestinal Microbiome | 3 | 2020 | 455 | 0.240 |
Why?
|
| Cerebral Ventriculitis | 1 | 2023 | 1 | 0.240 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 2 | 2020 | 294 | 0.240 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2019 | 378 | 0.240 |
Why?
|
| Zebrafish | 3 | 2021 | 309 | 0.240 |
Why?
|
| Spinal Cord | 2 | 1999 | 249 | 0.240 |
Why?
|
| Astrocytes | 2 | 2021 | 139 | 0.240 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2009 | 582 | 0.230 |
Why?
|
| Encephalitis | 2 | 2015 | 104 | 0.230 |
Why?
|
| Immunohistochemistry | 6 | 2009 | 1753 | 0.230 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 3 | 2022 | 63 | 0.230 |
Why?
|
| Inflammation Mediators | 2 | 2021 | 154 | 0.230 |
Why?
|
| Angiography | 3 | 2011 | 208 | 0.220 |
Why?
|
| Postoperative Hemorrhage | 2 | 2016 | 46 | 0.220 |
Why?
|
| Genes, Dominant | 3 | 2001 | 117 | 0.220 |
Why?
|
| White Matter | 2 | 2020 | 80 | 0.220 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2001 | 153 | 0.220 |
Why?
|
| Cerebellum | 3 | 2018 | 247 | 0.220 |
Why?
|
| Circulating MicroRNA | 1 | 2022 | 12 | 0.220 |
Why?
|
| Occipital Lobe | 2 | 1999 | 24 | 0.210 |
Why?
|
| Germ-Line Mutation | 1 | 2005 | 329 | 0.210 |
Why?
|
| Leukoaraiosis | 1 | 2021 | 3 | 0.210 |
Why?
|
| Endarterectomy, Carotid | 2 | 2000 | 73 | 0.210 |
Why?
|
| Fibrinolysis | 1 | 2022 | 35 | 0.210 |
Why?
|
| Predictive Value of Tests | 5 | 2021 | 1673 | 0.210 |
Why?
|
| Apoptosis | 2 | 2019 | 1683 | 0.210 |
Why?
|
| Cerebral Small Vessel Diseases | 1 | 2021 | 7 | 0.210 |
Why?
|
| Databases, Factual | 3 | 2021 | 814 | 0.210 |
Why?
|
| Electrodes | 2 | 1992 | 78 | 0.200 |
Why?
|
| Cell Culture Techniques | 2 | 2001 | 188 | 0.200 |
Why?
|
| Health Services | 1 | 2002 | 55 | 0.200 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2012 | 2438 | 0.200 |
Why?
|
| Epoprostenol | 3 | 1989 | 46 | 0.200 |
Why?
|
| Recovery of Function | 2 | 2020 | 272 | 0.200 |
Why?
|
| Morbidity | 1 | 2021 | 148 | 0.200 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2017 | 663 | 0.200 |
Why?
|
| G-Protein-Coupled Receptor Kinase 2 | 1 | 2021 | 22 | 0.200 |
Why?
|
| Receptors, Growth Factor | 1 | 2001 | 52 | 0.200 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 2021 | 36 | 0.200 |
Why?
|
| Patient Participation | 1 | 2023 | 216 | 0.190 |
Why?
|
| ADAMTS5 Protein | 1 | 2020 | 4 | 0.190 |
Why?
|
| Versicans | 1 | 2020 | 6 | 0.190 |
Why?
|
| Perfusion Imaging | 1 | 2021 | 50 | 0.190 |
Why?
|
| Microfilament Proteins | 3 | 2018 | 208 | 0.190 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2019 | 381 | 0.190 |
Why?
|
| Genetic Markers | 5 | 2005 | 476 | 0.190 |
Why?
|
| Vascular Diseases | 3 | 2017 | 121 | 0.190 |
Why?
|
| Research | 1 | 2002 | 253 | 0.190 |
Why?
|
| Aging | 3 | 2020 | 691 | 0.190 |
Why?
|
| Toll-Like Receptor 4 | 2 | 2019 | 88 | 0.190 |
Why?
|
| Plasminogen Activators | 1 | 2000 | 11 | 0.190 |
Why?
|
| Mice, Mutant Strains | 3 | 2010 | 229 | 0.190 |
Why?
|
| Tumor Microenvironment | 1 | 2024 | 418 | 0.190 |
Why?
|
| Frontal Lobe | 3 | 2003 | 130 | 0.180 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 2000 | 47 | 0.180 |
Why?
|
| Genetic Therapy | 2 | 2017 | 342 | 0.180 |
Why?
|
| Bayes Theorem | 4 | 2022 | 361 | 0.180 |
Why?
|
| Thrombectomy | 2 | 2023 | 158 | 0.180 |
Why?
|
| Time-to-Treatment | 1 | 2021 | 98 | 0.180 |
Why?
|
| Balloon Occlusion | 1 | 2000 | 27 | 0.180 |
Why?
|
| Neurotoxins | 1 | 2020 | 49 | 0.180 |
Why?
|
| Proof of Concept Study | 1 | 2019 | 38 | 0.180 |
Why?
|
| Self Report | 1 | 2021 | 288 | 0.180 |
Why?
|
| Anticoagulants | 2 | 2024 | 408 | 0.180 |
Why?
|
| Chronic Disease | 4 | 2020 | 971 | 0.180 |
Why?
|
| Head Injuries, Penetrating | 1 | 2020 | 54 | 0.180 |
Why?
|
| Meningeal Neoplasms | 3 | 1990 | 61 | 0.180 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2021 | 159 | 0.180 |
Why?
|
| rhoA GTP-Binding Protein | 3 | 2020 | 83 | 0.180 |
Why?
|
| Cell Membrane Permeability | 2 | 2018 | 119 | 0.180 |
Why?
|
| Abnormalities, Radiation-Induced | 1 | 1999 | 2 | 0.180 |
Why?
|
| Germinoma | 1 | 1999 | 3 | 0.180 |
Why?
|
| Wounds, Gunshot | 1 | 2020 | 71 | 0.170 |
Why?
|
| Infant | 8 | 2014 | 3046 | 0.170 |
Why?
|
| Endovascular Procedures | 2 | 2013 | 218 | 0.170 |
Why?
|
| Botulinum Toxins, Type A | 1 | 2020 | 49 | 0.170 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2011 | 2357 | 0.170 |
Why?
|
| Autoantigens | 1 | 2020 | 127 | 0.170 |
Why?
|
| Thalamus | 3 | 2022 | 132 | 0.170 |
Why?
|
| Neurosurgeons | 1 | 2019 | 25 | 0.170 |
Why?
|
| MAP Kinase Signaling System | 2 | 2019 | 192 | 0.170 |
Why?
|
| Protein C | 1 | 2018 | 5 | 0.170 |
Why?
|
| Thrombomodulin | 1 | 2018 | 7 | 0.170 |
Why?
|
| Case-Control Studies | 3 | 2021 | 1805 | 0.170 |
Why?
|
| Autoantibodies | 1 | 2020 | 267 | 0.170 |
Why?
|
| Visual Fields | 2 | 1998 | 98 | 0.170 |
Why?
|
| Intracranial Hypotension | 1 | 1998 | 3 | 0.170 |
Why?
|
| Cranial Fossa, Posterior | 1 | 2018 | 25 | 0.170 |
Why?
|
| Zinc | 1 | 2019 | 91 | 0.170 |
Why?
|
| Age Factors | 6 | 2016 | 1851 | 0.170 |
Why?
|
| Critical Pathways | 1 | 1999 | 35 | 0.170 |
Why?
|
| Cranial Fossa, Middle | 1 | 2018 | 11 | 0.170 |
Why?
|
| Cation Transport Proteins | 1 | 2019 | 64 | 0.170 |
Why?
|
| Disease Susceptibility | 2 | 2017 | 193 | 0.170 |
Why?
|
| Pedigree | 7 | 2011 | 966 | 0.160 |
Why?
|
| Vision Disorders | 2 | 1998 | 75 | 0.160 |
Why?
|
| Arterial Occlusive Diseases | 3 | 1984 | 107 | 0.160 |
Why?
|
| Adaptation, Physiological | 1 | 2021 | 306 | 0.160 |
Why?
|
| Intraoperative Complications | 1 | 2000 | 185 | 0.160 |
Why?
|
| Neurosciences | 1 | 2019 | 52 | 0.160 |
Why?
|
| Amobarbital | 2 | 1995 | 5 | 0.160 |
Why?
|
| Artificial Intelligence | 1 | 2021 | 298 | 0.160 |
Why?
|
| Myosin Type II | 1 | 2018 | 50 | 0.160 |
Why?
|
| Quality of Life | 2 | 2023 | 1585 | 0.160 |
Why?
|
| Memory Disorders | 3 | 1995 | 69 | 0.160 |
Why?
|
| Suction | 3 | 2013 | 35 | 0.160 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2021 | 466 | 0.160 |
Why?
|
| T-Lymphocytes | 3 | 2018 | 1195 | 0.160 |
Why?
|
| Algorithms | 2 | 2008 | 1830 | 0.160 |
Why?
|
| Thrombospondin 1 | 1 | 2017 | 21 | 0.160 |
Why?
|
| Caenorhabditis elegans Proteins | 1 | 2019 | 109 | 0.160 |
Why?
|
| Research Design | 3 | 2019 | 594 | 0.160 |
Why?
|
| Glioma | 3 | 1998 | 285 | 0.160 |
Why?
|
| Depression | 1 | 2021 | 473 | 0.150 |
Why?
|
| Gastrointestinal Tract | 1 | 2019 | 191 | 0.150 |
Why?
|
| Genetic Counseling | 3 | 2005 | 100 | 0.150 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2017 | 44 | 0.150 |
Why?
|
| Mice, Inbred C57BL | 6 | 2020 | 3092 | 0.150 |
Why?
|
| Guidelines as Topic | 2 | 2014 | 162 | 0.150 |
Why?
|
| MicroRNAs | 1 | 2022 | 534 | 0.150 |
Why?
|
| DNA Mutational Analysis | 5 | 2011 | 526 | 0.150 |
Why?
|
| Electrodes, Implanted | 4 | 1994 | 171 | 0.150 |
Why?
|
| Therapeutic Irrigation | 1 | 2017 | 60 | 0.150 |
Why?
|
| Pilot Projects | 2 | 2020 | 839 | 0.150 |
Why?
|
| Intestinal Mucosa | 2 | 2019 | 797 | 0.150 |
Why?
|
| Sodium Chloride | 1 | 2017 | 88 | 0.150 |
Why?
|
| Emergency Service, Hospital | 1 | 2021 | 484 | 0.150 |
Why?
|
| Cells, Cultured | 3 | 2021 | 2818 | 0.150 |
Why?
|
| Blood-Brain Barrier | 3 | 1994 | 70 | 0.140 |
Why?
|
| Permeability | 3 | 2021 | 137 | 0.140 |
Why?
|
| Histological Techniques | 1 | 2016 | 35 | 0.140 |
Why?
|
| Temporal Arteries | 2 | 2009 | 9 | 0.140 |
Why?
|
| Corpus Callosum | 2 | 2003 | 56 | 0.140 |
Why?
|
| Circle of Willis | 1 | 1996 | 5 | 0.140 |
Why?
|
| Antigens, CD | 2 | 2014 | 458 | 0.140 |
Why?
|
| Cluster Analysis | 1 | 2017 | 369 | 0.140 |
Why?
|
| Prevalence | 7 | 2023 | 1239 | 0.140 |
Why?
|
| Iodine | 1 | 2016 | 43 | 0.140 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2009 | 879 | 0.140 |
Why?
|
| Blood Coagulation | 2 | 2018 | 91 | 0.140 |
Why?
|
| Neuroanatomy | 1 | 1995 | 4 | 0.140 |
Why?
|
| Memory | 3 | 1995 | 225 | 0.140 |
Why?
|
| Reference Values | 3 | 2002 | 674 | 0.140 |
Why?
|
| Endarterectomy | 3 | 1991 | 20 | 0.140 |
Why?
|
| Point Mutation | 2 | 2009 | 246 | 0.140 |
Why?
|
| Demography | 1 | 2016 | 177 | 0.130 |
Why?
|
| Organ Size | 1 | 2016 | 364 | 0.130 |
Why?
|
| Somatosensory Cortex | 1 | 1997 | 129 | 0.130 |
Why?
|
| Hospitalization | 1 | 2021 | 849 | 0.130 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1995 | 135 | 0.130 |
Why?
|
| Cell Differentiation | 1 | 2001 | 1458 | 0.130 |
Why?
|
| C-Reactive Protein | 1 | 2016 | 190 | 0.130 |
Why?
|
| Keratin-1 | 1 | 2014 | 2 | 0.130 |
Why?
|
| MutS Homolog 2 Protein | 2 | 2011 | 30 | 0.130 |
Why?
|
| Angioplasty | 2 | 2005 | 70 | 0.130 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 4 | 1998 | 92 | 0.130 |
Why?
|
| Chromosome Aberrations | 1 | 1996 | 387 | 0.130 |
Why?
|
| Laser Capture Microdissection | 1 | 2014 | 20 | 0.120 |
Why?
|
| Proportional Hazards Models | 3 | 2017 | 859 | 0.120 |
Why?
|
| Stress Fibers | 1 | 2014 | 23 | 0.120 |
Why?
|
| Voice | 1 | 1994 | 20 | 0.120 |
Why?
|
| American Heart Association | 3 | 2014 | 92 | 0.120 |
Why?
|
| Single-Chain Antibodies | 1 | 2014 | 17 | 0.120 |
Why?
|
| Neoplasm Staging | 2 | 2012 | 1939 | 0.120 |
Why?
|
| Magnetic Resonance Angiography | 3 | 2020 | 262 | 0.120 |
Why?
|
| Cell Proliferation | 2 | 2014 | 1578 | 0.120 |
Why?
|
| Pseudotumor Cerebri | 1 | 1994 | 16 | 0.120 |
Why?
|
| Inflammation | 2 | 2011 | 920 | 0.120 |
Why?
|
| Chorea | 1 | 2014 | 13 | 0.120 |
Why?
|
| Visual Cortex | 1 | 1997 | 251 | 0.120 |
Why?
|
| History, 21st Century | 2 | 2019 | 175 | 0.120 |
Why?
|
| Survival Rate | 2 | 2009 | 1863 | 0.120 |
Why?
|
| Logistic Models | 4 | 2021 | 1186 | 0.120 |
Why?
|
| Carotid Stenosis | 4 | 2005 | 112 | 0.120 |
Why?
|
| Music | 1 | 1994 | 34 | 0.120 |
Why?
|
| Subthalamic Nucleus | 1 | 2014 | 22 | 0.120 |
Why?
|
| Immunity, Innate | 1 | 2017 | 409 | 0.120 |
Why?
|
| History, 20th Century | 2 | 2019 | 312 | 0.120 |
Why?
|
| Gadolinium | 1 | 2013 | 103 | 0.110 |
Why?
|
| Polymerase Chain Reaction | 3 | 2008 | 927 | 0.110 |
Why?
|
| Prostaglandins | 2 | 1983 | 43 | 0.110 |
Why?
|
| Decompression, Surgical | 2 | 2006 | 87 | 0.110 |
Why?
|
| Deep Brain Stimulation | 1 | 2014 | 54 | 0.110 |
Why?
|
| Chicago | 1 | 2017 | 1379 | 0.110 |
Why?
|
| Women's Health | 1 | 2014 | 100 | 0.110 |
Why?
|
| Polymorphism, Genetic | 2 | 2003 | 819 | 0.110 |
Why?
|
| Spinal Cord Compression | 2 | 2000 | 27 | 0.110 |
Why?
|
| Angiography, Digital Subtraction | 2 | 2011 | 92 | 0.110 |
Why?
|
| Gene Deletion | 3 | 2020 | 329 | 0.110 |
Why?
|
| Cross-Sectional Studies | 1 | 2017 | 1621 | 0.110 |
Why?
|
| Macrophages | 2 | 2021 | 554 | 0.110 |
Why?
|
| Intercellular Junctions | 2 | 2010 | 68 | 0.110 |
Why?
|
| Actins | 4 | 2005 | 451 | 0.110 |
Why?
|
| Stents | 3 | 2005 | 377 | 0.110 |
Why?
|
| Fibroblast Growth Factor 2 | 3 | 2004 | 57 | 0.100 |
Why?
|
| Data Interpretation, Statistical | 1 | 2013 | 297 | 0.100 |
Why?
|
| Vinblastine | 1 | 2012 | 108 | 0.100 |
Why?
|
| Bleomycin | 1 | 2012 | 98 | 0.100 |
Why?
|
| Disease Management | 3 | 2020 | 327 | 0.100 |
Why?
|
| Jews | 1 | 2011 | 42 | 0.100 |
Why?
|
| Dura Mater | 2 | 1996 | 44 | 0.100 |
Why?
|
| Dacarbazine | 1 | 2012 | 102 | 0.100 |
Why?
|
| Incidental Findings | 1 | 2011 | 95 | 0.100 |
Why?
|
| Illinois | 2 | 2011 | 462 | 0.100 |
Why?
|
| Sirolimus | 2 | 2023 | 169 | 0.100 |
Why?
|
| Societies, Medical | 2 | 2014 | 572 | 0.100 |
Why?
|
| Incidence | 4 | 2013 | 1577 | 0.100 |
Why?
|
| Doxorubicin | 1 | 2012 | 295 | 0.100 |
Why?
|
| Sequence Analysis, DNA | 2 | 2023 | 853 | 0.100 |
Why?
|
| Perfusion | 2 | 2021 | 203 | 0.100 |
Why?
|
| Myosin Heavy Chains | 2 | 2020 | 88 | 0.100 |
Why?
|
| Radiotherapy Dosage | 1 | 2012 | 468 | 0.100 |
Why?
|
| Cerebral Arterial Diseases | 2 | 1995 | 6 | 0.090 |
Why?
|
| Echo-Planar Imaging | 1 | 2010 | 52 | 0.090 |
Why?
|
| Receptors, TIE | 2 | 2001 | 2 | 0.090 |
Why?
|
| Receptor, TIE-1 | 2 | 2001 | 2 | 0.090 |
Why?
|
| Recombinant Proteins | 4 | 2013 | 1014 | 0.090 |
Why?
|
| Muscular Diseases | 1 | 1990 | 63 | 0.090 |
Why?
|
| Migraine Disorders | 2 | 2020 | 40 | 0.090 |
Why?
|
| Receptor, TIE-2 | 2 | 2001 | 15 | 0.090 |
Why?
|
| Spinal Puncture | 1 | 1990 | 38 | 0.090 |
Why?
|
| RNA Splicing | 1 | 2011 | 142 | 0.090 |
Why?
|
| Recurrence | 6 | 1996 | 1139 | 0.090 |
Why?
|
| von Willebrand Factor | 2 | 2001 | 37 | 0.090 |
Why?
|
| Glasgow Coma Scale | 2 | 2000 | 65 | 0.090 |
Why?
|
| Equipment Design | 3 | 2000 | 406 | 0.090 |
Why?
|
| Genomics | 2 | 2021 | 720 | 0.090 |
Why?
|
| Fatal Outcome | 1 | 2010 | 293 | 0.090 |
Why?
|
| Gene Expression Regulation, Developmental | 3 | 2021 | 623 | 0.090 |
Why?
|
| Animals, Genetically Modified | 2 | 2021 | 181 | 0.090 |
Why?
|
| Medical History Taking | 1 | 1990 | 80 | 0.090 |
Why?
|
| Phosphorylation | 3 | 2019 | 1106 | 0.090 |
Why?
|
| Genetic Linkage | 5 | 2001 | 623 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 860 | 0.090 |
Why?
|
| Basal Ganglia | 1 | 2009 | 42 | 0.090 |
Why?
|
| Patient Admission | 1 | 1990 | 112 | 0.090 |
Why?
|
| HLA-DR Antigens | 1 | 2009 | 61 | 0.090 |
Why?
|
| Spinal Cord Diseases | 2 | 2000 | 29 | 0.090 |
Why?
|
| Polyurethanes | 1 | 2008 | 10 | 0.080 |
Why?
|
| Ethers | 1 | 2008 | 14 | 0.080 |
Why?
|
| Disease-Free Survival | 1 | 2012 | 1204 | 0.080 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 2008 | 49 | 0.080 |
Why?
|
| Microdissection | 1 | 2008 | 18 | 0.080 |
Why?
|
| Brachial Plexus | 1 | 2008 | 3 | 0.080 |
Why?
|
| Weights and Measures | 1 | 2008 | 7 | 0.080 |
Why?
|
| Immunoglobulin A | 1 | 2009 | 80 | 0.080 |
Why?
|
| Collagen | 4 | 2005 | 269 | 0.080 |
Why?
|
| Medical Illustration | 1 | 2008 | 16 | 0.080 |
Why?
|
| Pulsatile Flow | 1 | 2008 | 49 | 0.080 |
Why?
|
| Umbilical Cord | 1 | 2008 | 40 | 0.080 |
Why?
|
| Magnetics | 1 | 2008 | 41 | 0.080 |
Why?
|
| Meningioma | 1 | 1989 | 60 | 0.080 |
Why?
|
| Respiratory Paralysis | 1 | 2008 | 8 | 0.080 |
Why?
|
| Basilar Artery | 2 | 2005 | 41 | 0.080 |
Why?
|
| Gene Targeting | 1 | 2008 | 72 | 0.080 |
Why?
|
| Base Sequence | 3 | 2011 | 2330 | 0.080 |
Why?
|
| Thrombosis | 1 | 2011 | 296 | 0.080 |
Why?
|
| Organ Culture Techniques | 1 | 2008 | 135 | 0.080 |
Why?
|
| Lasers | 1 | 2008 | 106 | 0.080 |
Why?
|
| United States | 8 | 2014 | 6672 | 0.080 |
Why?
|
| Immunity, Cellular | 1 | 2009 | 177 | 0.080 |
Why?
|
| DNA, Complementary | 1 | 2009 | 393 | 0.080 |
Why?
|
| Fluorocarbons | 1 | 2008 | 72 | 0.080 |
Why?
|
| Japan | 1 | 2008 | 307 | 0.080 |
Why?
|
| Radiation Dosage | 1 | 2009 | 227 | 0.080 |
Why?
|
| Alcoholism | 1 | 1990 | 172 | 0.080 |
Why?
|
| Nerve Block | 1 | 2008 | 51 | 0.080 |
Why?
|
| Neoplasms, Radiation-Induced | 2 | 2004 | 109 | 0.080 |
Why?
|
| Lipopolysaccharide Receptors | 2 | 2018 | 23 | 0.080 |
Why?
|
| Vertebrobasilar Insufficiency | 2 | 2005 | 16 | 0.080 |
Why?
|
| Ultrasonography, Interventional | 1 | 2008 | 121 | 0.080 |
Why?
|
| Anesthetics, Local | 1 | 2008 | 76 | 0.080 |
Why?
|
| Postoperative Period | 5 | 1992 | 303 | 0.080 |
Why?
|
| Angiogenesis Inducing Agents | 2 | 1999 | 30 | 0.080 |
Why?
|
| Smoking | 1 | 2011 | 609 | 0.080 |
Why?
|
| Stress, Mechanical | 1 | 2008 | 248 | 0.080 |
Why?
|
| Regional Blood Flow | 3 | 1998 | 197 | 0.080 |
Why?
|
| Lipopolysaccharides | 2 | 2020 | 286 | 0.080 |
Why?
|
| Animals, Newborn | 2 | 2021 | 510 | 0.080 |
Why?
|
| Gliosis | 4 | 2000 | 35 | 0.080 |
Why?
|
| Hemodilution | 1 | 1987 | 13 | 0.080 |
Why?
|
| Cell Adhesion | 1 | 2008 | 420 | 0.080 |
Why?
|
| Patient Care Team | 2 | 2000 | 280 | 0.070 |
Why?
|
| Sequence Deletion | 1 | 2007 | 205 | 0.070 |
Why?
|
| Survival Analysis | 2 | 2009 | 1538 | 0.070 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2008 | 579 | 0.070 |
Why?
|
| Colorado | 1 | 2006 | 35 | 0.070 |
Why?
|
| Exons | 2 | 2007 | 450 | 0.070 |
Why?
|
| Arachnoid | 1 | 1986 | 3 | 0.070 |
Why?
|
| HEK293 Cells | 2 | 2020 | 615 | 0.070 |
Why?
|
| Antihypertensive Agents | 3 | 2024 | 521 | 0.070 |
Why?
|
| Pia Mater | 1 | 1986 | 5 | 0.070 |
Why?
|
| Intestines | 2 | 2020 | 411 | 0.070 |
Why?
|
| Genes | 2 | 1998 | 305 | 0.070 |
Why?
|
| Tissue Engineering | 1 | 2008 | 181 | 0.070 |
Why?
|
| Microsurgery | 4 | 2005 | 84 | 0.070 |
Why?
|
| Case Management | 1 | 2006 | 24 | 0.070 |
Why?
|
| Cerebellar Neoplasms | 1 | 1986 | 36 | 0.070 |
Why?
|
| Fibronectins | 2 | 2005 | 93 | 0.070 |
Why?
|
| Inheritance Patterns | 1 | 2006 | 48 | 0.070 |
Why?
|
| Molecular Sequence Data | 2 | 2005 | 3030 | 0.070 |
Why?
|
| Tomography Scanners, X-Ray Computed | 2 | 2017 | 20 | 0.070 |
Why?
|
| Appointments and Schedules | 1 | 2006 | 53 | 0.070 |
Why?
|
| Immunoenzyme Techniques | 3 | 2002 | 303 | 0.070 |
Why?
|
| Heterozygote | 1 | 2006 | 365 | 0.070 |
Why?
|
| Up-Regulation | 2 | 2011 | 712 | 0.070 |
Why?
|
| Intracranial Arterial Diseases | 1 | 2005 | 3 | 0.070 |
Why?
|
| Fibromuscular Dysplasia | 1 | 2005 | 11 | 0.070 |
Why?
|
| Hypertension, Renovascular | 1 | 2005 | 14 | 0.070 |
Why?
|
| Cerebellar Diseases | 1 | 2005 | 20 | 0.070 |
Why?
|
| Vertebral Artery | 1 | 2005 | 23 | 0.070 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2009 | 689 | 0.060 |
Why?
|
| Odds Ratio | 2 | 2017 | 678 | 0.060 |
Why?
|
| Renal Artery Obstruction | 1 | 2005 | 39 | 0.060 |
Why?
|
| Radial Artery | 1 | 2005 | 33 | 0.060 |
Why?
|
| Skull | 2 | 2020 | 249 | 0.060 |
Why?
|
| Ki-67 Antigen | 1 | 2005 | 64 | 0.060 |
Why?
|
| Family | 1 | 2006 | 311 | 0.060 |
Why?
|
| Dexamethasone | 2 | 2019 | 326 | 0.060 |
Why?
|
| Perioperative Care | 1 | 2006 | 161 | 0.060 |
Why?
|
| Epilepsy, Complex Partial | 2 | 1995 | 7 | 0.060 |
Why?
|
| Nocardia Infections | 1 | 1984 | 5 | 0.060 |
Why?
|
| Laminin | 1 | 2005 | 85 | 0.060 |
Why?
|
| Disability Evaluation | 2 | 2017 | 136 | 0.060 |
Why?
|
| Registries | 2 | 2006 | 702 | 0.060 |
Why?
|
| Pregnancy | 1 | 2011 | 2894 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 2 | 2022 | 1376 | 0.060 |
Why?
|
| Myosins | 1 | 2005 | 90 | 0.060 |
Why?
|
| Osteomyelitis | 1 | 1984 | 54 | 0.060 |
Why?
|
| Network Meta-Analysis | 1 | 2024 | 7 | 0.060 |
Why?
|
| Diagnostic Imaging | 4 | 2008 | 469 | 0.060 |
Why?
|
| Angiopoietins | 1 | 2004 | 6 | 0.060 |
Why?
|
| Probability | 2 | 2023 | 355 | 0.060 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2004 | 67 | 0.060 |
Why?
|
| Movement Disorders | 2 | 2008 | 44 | 0.060 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2005 | 315 | 0.060 |
Why?
|
| Cytoskeletal Proteins | 1 | 2005 | 223 | 0.060 |
Why?
|
| Length of Stay | 2 | 2012 | 702 | 0.060 |
Why?
|
| Sturge-Weber Syndrome | 2 | 2001 | 8 | 0.060 |
Why?
|
| Radiography | 4 | 2009 | 813 | 0.060 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2004 | 84 | 0.060 |
Why?
|
| Spondylolisthesis | 1 | 2003 | 12 | 0.060 |
Why?
|
| Risk | 4 | 2003 | 674 | 0.060 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2004 | 179 | 0.060 |
Why?
|
| Intervertebral Disc Displacement | 1 | 2003 | 24 | 0.060 |
Why?
|
| Indomethacin | 1 | 1983 | 59 | 0.060 |
Why?
|
| ROC Curve | 2 | 2018 | 752 | 0.060 |
Why?
|
| Spinal Stenosis | 1 | 2003 | 26 | 0.060 |
Why?
|
| Glasgow Outcome Scale | 1 | 2022 | 7 | 0.060 |
Why?
|
| Integrin beta1 | 1 | 2022 | 33 | 0.060 |
Why?
|
| Sensation Disorders | 2 | 2008 | 23 | 0.050 |
Why?
|
| Integrins | 1 | 2022 | 76 | 0.050 |
Why?
|
| Comorbidity | 3 | 2003 | 943 | 0.050 |
Why?
|
| Genetic Testing | 1 | 2006 | 535 | 0.050 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2023 | 262 | 0.050 |
Why?
|
| Carotid Artery Injuries | 1 | 1982 | 22 | 0.050 |
Why?
|
| Blood Pressure | 2 | 1990 | 1143 | 0.050 |
Why?
|
| Collateral Circulation | 1 | 1982 | 35 | 0.050 |
Why?
|
| Forecasting | 2 | 2002 | 304 | 0.050 |
Why?
|
| Lumbar Vertebrae | 1 | 2003 | 148 | 0.050 |
Why?
|
| Infusions, Intraventricular | 1 | 2021 | 5 | 0.050 |
Why?
|
| Coronary Disease | 1 | 2003 | 261 | 0.050 |
Why?
|
| Arteriosclerosis | 1 | 1982 | 113 | 0.050 |
Why?
|
| Observational Studies as Topic | 1 | 2022 | 48 | 0.050 |
Why?
|
| Headache | 3 | 2001 | 73 | 0.050 |
Why?
|
| Smooth Muscle Myosins | 1 | 2001 | 5 | 0.050 |
Why?
|
| Culture Techniques | 1 | 2001 | 91 | 0.050 |
Why?
|
| Transforming Growth Factor beta | 1 | 2004 | 301 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 1 | 2009 | 1036 | 0.050 |
Why?
|
| Mesencephalon | 1 | 2002 | 64 | 0.050 |
Why?
|
| Gain of Function Mutation | 1 | 2021 | 13 | 0.050 |
Why?
|
| Alleles | 1 | 2005 | 1128 | 0.050 |
Why?
|
| In Situ Hybridization | 1 | 2002 | 307 | 0.050 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2021 | 29 | 0.050 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2001 | 18 | 0.050 |
Why?
|
| Down-Regulation | 1 | 2003 | 504 | 0.050 |
Why?
|
| Hamartoma | 1 | 2001 | 31 | 0.050 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2021 | 88 | 0.050 |
Why?
|
| Cyclooxygenase 2 | 1 | 2021 | 100 | 0.050 |
Why?
|
| Technetium Tc 99m Exametazime | 2 | 1998 | 5 | 0.050 |
Why?
|
| Mosaicism | 1 | 2021 | 67 | 0.050 |
Why?
|
| Congenital Abnormalities | 1 | 2001 | 63 | 0.050 |
Why?
|
| Single-Blind Method | 2 | 2019 | 153 | 0.050 |
Why?
|
| Cushing Syndrome | 1 | 2000 | 24 | 0.050 |
Why?
|
| Primary Cell Culture | 1 | 2021 | 72 | 0.050 |
Why?
|
| Loss of Function Mutation | 1 | 2021 | 42 | 0.050 |
Why?
|
| ADAMTS4 Protein | 1 | 2020 | 4 | 0.050 |
Why?
|
| Amino Acid Sequence | 1 | 2005 | 2062 | 0.050 |
Why?
|
| ADAMTS1 Protein | 1 | 2020 | 6 | 0.050 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2001 | 70 | 0.050 |
Why?
|
| Arteries | 2 | 2005 | 176 | 0.050 |
Why?
|
| RNA | 1 | 2005 | 560 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 1987 | 1313 | 0.050 |
Why?
|
| Hospital Charges | 1 | 2000 | 29 | 0.050 |
Why?
|
| Mice, Inbred DBA | 1 | 2020 | 148 | 0.050 |
Why?
|
| Cyclic N-Oxides | 1 | 2020 | 33 | 0.050 |
Why?
|
| Gene Silencing | 1 | 2021 | 172 | 0.050 |
Why?
|
| Life Support Care | 1 | 2021 | 49 | 0.050 |
Why?
|
| Neuroimaging | 1 | 2021 | 113 | 0.050 |
Why?
|
| Extracellular Space | 2 | 1994 | 90 | 0.050 |
Why?
|
| Cholecalciferol | 1 | 2020 | 35 | 0.050 |
Why?
|
| Plasma | 1 | 2020 | 50 | 0.050 |
Why?
|
| Vimentin | 1 | 2020 | 44 | 0.050 |
Why?
|
| Healthy Volunteers | 1 | 2021 | 143 | 0.050 |
Why?
|
| Hand | 1 | 2001 | 130 | 0.050 |
Why?
|
| Syndrome | 1 | 2001 | 446 | 0.050 |
Why?
|
| Spin Labels | 1 | 2020 | 102 | 0.050 |
Why?
|
| Proteolysis | 1 | 2020 | 100 | 0.050 |
Why?
|
| Tubulin | 1 | 2020 | 58 | 0.050 |
Why?
|
| Constriction | 1 | 2000 | 27 | 0.050 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2021 | 151 | 0.050 |
Why?
|
| Surgical Procedures, Operative | 1 | 1982 | 182 | 0.050 |
Why?
|
| Nevus of Ota | 1 | 1999 | 1 | 0.050 |
Why?
|
| Intraoperative Care | 1 | 2000 | 82 | 0.050 |
Why?
|
| Ligation | 1 | 2000 | 51 | 0.050 |
Why?
|
| Electric Stimulation | 3 | 1999 | 347 | 0.050 |
Why?
|
| Withholding Treatment | 1 | 2021 | 112 | 0.050 |
Why?
|
| Eyelid Neoplasms | 1 | 1999 | 6 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2001 | 91 | 0.050 |
Why?
|
| Endothelium | 1 | 2020 | 59 | 0.050 |
Why?
|
| Warfarin | 1 | 2020 | 103 | 0.050 |
Why?
|
| Intraoperative Period | 2 | 1990 | 90 | 0.050 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2021 | 182 | 0.040 |
Why?
|
| Dextran Sulfate | 1 | 2019 | 68 | 0.040 |
Why?
|
| Nitric Oxide | 1 | 2021 | 278 | 0.040 |
Why?
|
| Drug Resistant Epilepsy | 1 | 2020 | 42 | 0.040 |
Why?
|
| Endothelial Growth Factors | 2 | 1996 | 55 | 0.040 |
Why?
|
| Models, Biological | 3 | 2020 | 1749 | 0.040 |
Why?
|
| Terminology as Topic | 1 | 2001 | 217 | 0.040 |
Why?
|
| Polycystic Kidney, Autosomal Dominant | 1 | 2001 | 136 | 0.040 |
Why?
|
| Metagenomics | 1 | 2020 | 83 | 0.040 |
Why?
|
| Databases, Bibliographic | 2 | 2009 | 17 | 0.040 |
Why?
|
| Morphogenesis | 1 | 2001 | 192 | 0.040 |
Why?
|
| Abnormalities, Multiple | 1 | 2001 | 232 | 0.040 |
Why?
|
| Models, Neurological | 2 | 2021 | 405 | 0.040 |
Why?
|
| Protein Binding | 2 | 2016 | 1456 | 0.040 |
Why?
|
| Antibodies | 1 | 2001 | 350 | 0.040 |
Why?
|
| Neutrophils | 1 | 2021 | 307 | 0.040 |
Why?
|
| Herniorrhaphy | 1 | 2000 | 79 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase 7 | 1 | 2019 | 21 | 0.040 |
Why?
|
| DNA, Bacterial | 1 | 2020 | 236 | 0.040 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2020 | 241 | 0.040 |
Why?
|
| Founder Effect | 2 | 2011 | 104 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2019 | 74 | 0.040 |
Why?
|
| Cysts | 1 | 2000 | 104 | 0.040 |
Why?
|
| Remission, Spontaneous | 1 | 1999 | 53 | 0.040 |
Why?
|
| Toll-Like Receptors | 1 | 2020 | 92 | 0.040 |
Why?
|
| Rupture, Spontaneous | 2 | 2006 | 43 | 0.040 |
Why?
|
| Endothelial Protein C Receptor | 1 | 2018 | 4 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2019 | 72 | 0.040 |
Why?
|
| Neuronal Plasticity | 1 | 2001 | 187 | 0.040 |
Why?
|
| Endoglin | 1 | 1998 | 20 | 0.040 |
Why?
|
| Auditory Cortex | 1 | 1999 | 58 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2007 | 1920 | 0.040 |
Why?
|
| Epithelium | 1 | 2020 | 319 | 0.040 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 1998 | 56 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 1998 | 54 | 0.040 |
Why?
|
| Reoperation | 2 | 1992 | 597 | 0.040 |
Why?
|
| Mutagenesis | 1 | 2019 | 199 | 0.040 |
Why?
|
| Genetic Association Studies | 1 | 2020 | 294 | 0.040 |
Why?
|
| Tight Junctions | 1 | 2020 | 149 | 0.040 |
Why?
|
| Motor Activity | 1 | 2001 | 327 | 0.040 |
Why?
|
| Auditory Perception | 1 | 1999 | 96 | 0.040 |
Why?
|
| Skin | 2 | 1999 | 554 | 0.040 |
Why?
|
| Caco-2 Cells | 1 | 2018 | 123 | 0.040 |
Why?
|
| Feces | 1 | 2020 | 319 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2021 | 349 | 0.040 |
Why?
|
| Ligands | 1 | 2019 | 433 | 0.040 |
Why?
|
| Occludin | 1 | 2018 | 66 | 0.040 |
Why?
|
| Injections, Intra-Arterial | 2 | 1995 | 33 | 0.040 |
Why?
|
| Gene Frequency | 2 | 2011 | 677 | 0.040 |
Why?
|
| Skull Base | 1 | 2018 | 47 | 0.040 |
Why?
|
| Sequence Alignment | 1 | 2019 | 351 | 0.040 |
Why?
|
| Computer Communication Networks | 1 | 1998 | 23 | 0.040 |
Why?
|
| Interleukin-1beta | 1 | 2018 | 78 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2019 | 684 | 0.040 |
Why?
|
| Creutzfeldt-Jakob Syndrome | 1 | 1997 | 25 | 0.040 |
Why?
|
| Computed Tomography Angiography | 1 | 2019 | 131 | 0.040 |
Why?
|
| Inpatients | 1 | 2021 | 297 | 0.040 |
Why?
|
| Homeostasis | 1 | 2020 | 409 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2018 | 334 | 0.040 |
Why?
|
| Chronic Pain | 1 | 2020 | 145 | 0.040 |
Why?
|
| Gram-Negative Bacteria | 1 | 2017 | 35 | 0.040 |
Why?
|
| Haplotypes | 2 | 2011 | 642 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2017 | 220 | 0.040 |
Why?
|
| Radiopharmaceuticals | 1 | 1998 | 180 | 0.040 |
Why?
|
| Emergency Treatment | 1 | 2017 | 39 | 0.040 |
Why?
|
| Phantoms, Imaging | 1 | 2019 | 429 | 0.040 |
Why?
|
| Germ-Free Life | 1 | 2017 | 69 | 0.040 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 1998 | 85 | 0.040 |
Why?
|
| Injections, Intravenous | 1 | 2017 | 244 | 0.040 |
Why?
|
| Caenorhabditis elegans | 1 | 2019 | 223 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2000 | 328 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2018 | 256 | 0.040 |
Why?
|
| Certification | 1 | 1997 | 58 | 0.040 |
Why?
|
| Gene Regulatory Networks | 1 | 2019 | 296 | 0.040 |
Why?
|
| Colitis | 1 | 2019 | 239 | 0.040 |
Why?
|
| Lung | 1 | 2023 | 1170 | 0.040 |
Why?
|
| Actin Cytoskeleton | 1 | 2018 | 192 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 999 | 0.040 |
Why?
|
| Constriction, Pathologic | 3 | 1995 | 213 | 0.040 |
Why?
|
| Erythrocytes | 1 | 2017 | 255 | 0.040 |
Why?
|
| ADAM Proteins | 1 | 2016 | 11 | 0.040 |
Why?
|
| RNA Interference | 1 | 2017 | 369 | 0.040 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 364 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2012 | 1961 | 0.030 |
Why?
|
| Chromosome Disorders | 1 | 1996 | 114 | 0.030 |
Why?
|
| Subtraction Technique | 2 | 1990 | 133 | 0.030 |
Why?
|
| Greece, Ancient | 1 | 1995 | 1 | 0.030 |
Why?
|
| Chromosome Mapping | 2 | 1998 | 1074 | 0.030 |
Why?
|
| Spinal Nerve Roots | 1 | 1995 | 17 | 0.030 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2016 | 54 | 0.030 |
Why?
|
| Respiratory Insufficiency | 2 | 2008 | 150 | 0.030 |
Why?
|
| Spinal Injuries | 1 | 1995 | 22 | 0.030 |
Why?
|
| Decision Making | 2 | 2000 | 642 | 0.030 |
Why?
|
| Neuropsychological Tests | 2 | 1995 | 502 | 0.030 |
Why?
|
| History, Ancient | 1 | 1995 | 74 | 0.030 |
Why?
|
| Analysis of Variance | 2 | 1995 | 912 | 0.030 |
Why?
|
| Brain Injuries | 1 | 1998 | 161 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 2019 | 669 | 0.030 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2016 | 99 | 0.030 |
Why?
|
| Curriculum | 1 | 2000 | 539 | 0.030 |
Why?
|
| Melanoma | 1 | 1999 | 459 | 0.030 |
Why?
|
| Pain | 1 | 1998 | 391 | 0.030 |
Why?
|
| Sex Factors | 2 | 1990 | 1054 | 0.030 |
Why?
|
| Skin Neoplasms | 1 | 1999 | 546 | 0.030 |
Why?
|
| Syringomyelia | 2 | 1991 | 15 | 0.030 |
Why?
|
| Glucose | 1 | 2017 | 638 | 0.030 |
Why?
|
| Barbiturates | 1 | 1994 | 12 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 2 | 1995 | 1219 | 0.030 |
Why?
|
| Sensation | 1 | 1994 | 45 | 0.030 |
Why?
|
| Polycystic Kidney Diseases | 1 | 1994 | 21 | 0.030 |
Why?
|
| Intracranial Embolism and Thrombosis | 1 | 1994 | 14 | 0.030 |
Why?
|
| Cell Adhesion Molecules | 1 | 1995 | 163 | 0.030 |
Why?
|
| Water-Electrolyte Balance | 1 | 1994 | 66 | 0.030 |
Why?
|
| Causality | 1 | 1994 | 81 | 0.030 |
Why?
|
| Diffusion | 1 | 1994 | 93 | 0.030 |
Why?
|
| Arnold-Chiari Malformation | 2 | 1991 | 43 | 0.030 |
Why?
|
| Organotechnetium Compounds | 1 | 1993 | 10 | 0.030 |
Why?
|
| Oximes | 1 | 1993 | 14 | 0.030 |
Why?
|
| Panic Disorder | 1 | 1993 | 22 | 0.030 |
Why?
|
| Deoxyglucose | 1 | 1993 | 37 | 0.030 |
Why?
|
| Thromboxane A2 | 2 | 1983 | 10 | 0.030 |
Why?
|
| Dizziness | 1 | 1993 | 27 | 0.030 |
Why?
|
| Tomography, Emission-Computed | 1 | 1993 | 103 | 0.030 |
Why?
|
| Recombination, Genetic | 1 | 1995 | 439 | 0.030 |
Why?
|
| Seasons | 1 | 1994 | 223 | 0.030 |
Why?
|
| Risk Reduction Behavior | 2 | 2003 | 98 | 0.030 |
Why?
|
| Cats | 2 | 1983 | 303 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2001 | 2501 | 0.030 |
Why?
|
| Hypersensitivity, Delayed | 1 | 1992 | 25 | 0.030 |
Why?
|
| Xenon Radioisotopes | 2 | 1982 | 10 | 0.030 |
Why?
|
| Mannitol | 1 | 1992 | 49 | 0.030 |
Why?
|
| Brain Stem Infarctions | 1 | 2012 | 5 | 0.030 |
Why?
|
| Lateral Ventricles | 1 | 2012 | 12 | 0.030 |
Why?
|
| Ventriculoperitoneal Shunt | 1 | 2012 | 22 | 0.030 |
Why?
|
| Spinal Neoplasms | 1 | 1992 | 50 | 0.030 |
Why?
|
| Subdural Space | 1 | 1992 | 9 | 0.030 |
Why?
|
| Psychosurgery | 1 | 1992 | 13 | 0.030 |
Why?
|
| Dominance, Cerebral | 1 | 1992 | 66 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2012 | 159 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2020 | 1464 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 746 | 0.030 |
Why?
|
| Cognition | 2 | 1999 | 570 | 0.030 |
Why?
|
| Injections, Intraventricular | 1 | 2011 | 19 | 0.020 |
Why?
|
| Respiration Disorders | 1 | 2011 | 39 | 0.020 |
Why?
|
| France | 1 | 2011 | 47 | 0.020 |
Why?
|
| Placebos | 1 | 2011 | 218 | 0.020 |
Why?
|
| Facial Paralysis | 1 | 1991 | 17 | 0.020 |
Why?
|
| Angiomatosis | 1 | 1990 | 5 | 0.020 |
Why?
|
| Family Health | 1 | 2011 | 162 | 0.020 |
Why?
|
| Functional Laterality | 1 | 1991 | 201 | 0.020 |
Why?
|
| Models, Genetic | 1 | 1996 | 926 | 0.020 |
Why?
|
| Rats | 2 | 1995 | 3990 | 0.020 |
Why?
|
| Encephalocele | 1 | 1990 | 24 | 0.020 |
Why?
|
| Breeding | 1 | 2010 | 39 | 0.020 |
Why?
|
| Edema, Cardiac | 1 | 2010 | 3 | 0.020 |
Why?
|
| Cerebral Infarction | 3 | 1991 | 71 | 0.020 |
Why?
|
| Internship and Residency | 1 | 2000 | 1004 | 0.020 |
Why?
|
| Genome, Human | 1 | 1995 | 756 | 0.020 |
Why?
|
| Paraplegia | 1 | 1990 | 17 | 0.020 |
Why?
|
| Myosin Light Chains | 1 | 2010 | 29 | 0.020 |
Why?
|
| Meta-Analysis as Topic | 1 | 1990 | 87 | 0.020 |
Why?
|
| Animal Structures | 1 | 2010 | 22 | 0.020 |
Why?
|
| England | 1 | 1990 | 41 | 0.020 |
Why?
|
| Leg | 1 | 1990 | 137 | 0.020 |
Why?
|
| Video Recording | 1 | 1991 | 190 | 0.020 |
Why?
|
| Parietal Lobe | 1 | 1991 | 117 | 0.020 |
Why?
|
| Carotid Artery Thrombosis | 1 | 1989 | 5 | 0.020 |
Why?
|
| Pulmonary Edema | 1 | 2010 | 50 | 0.020 |
Why?
|
| DNA | 1 | 1995 | 1294 | 0.020 |
Why?
|
| Dementia | 1 | 1991 | 187 | 0.020 |
Why?
|
| Surgical Wound Dehiscence | 1 | 1989 | 37 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 1989 | 104 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 1989 | 274 | 0.020 |
Why?
|
| Consciousness Disorders | 1 | 2008 | 9 | 0.020 |
Why?
|
| Hippocampus | 1 | 1992 | 442 | 0.020 |
Why?
|
| Phrenic Nerve | 1 | 2008 | 42 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2010 | 547 | 0.020 |
Why?
|
| Immune System | 1 | 2009 | 93 | 0.020 |
Why?
|
| Monitoring, Intraoperative | 1 | 2008 | 109 | 0.020 |
Why?
|
| Italy | 1 | 2007 | 106 | 0.020 |
Why?
|
| Morphine | 1 | 2008 | 130 | 0.020 |
Why?
|
| Shoulder Joint | 1 | 2008 | 90 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2008 | 321 | 0.020 |
Why?
|
| DNA Primers | 1 | 2007 | 543 | 0.020 |
Why?
|
| Diagnosis, Differential | 3 | 1999 | 1565 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2008 | 916 | 0.020 |
Why?
|
| Psychology | 1 | 2006 | 24 | 0.020 |
Why?
|
| Random Allocation | 1 | 1986 | 332 | 0.020 |
Why?
|
| Pain, Postoperative | 1 | 2008 | 240 | 0.020 |
Why?
|
| Brachiocephalic Trunk | 1 | 2005 | 14 | 0.020 |
Why?
|
| Dilatation, Pathologic | 1 | 2005 | 54 | 0.020 |
Why?
|
| Regression Analysis | 1 | 1986 | 596 | 0.020 |
Why?
|
| Aortography | 1 | 2005 | 63 | 0.020 |
Why?
|
| Vasospasm, Intracranial | 1 | 2005 | 36 | 0.020 |
Why?
|
| Infarction, Middle Cerebral Artery | 1 | 2005 | 35 | 0.020 |
Why?
|
| Nocardia asteroides | 1 | 1984 | 2 | 0.020 |
Why?
|
| Sulfadiazine | 1 | 1984 | 24 | 0.020 |
Why?
|
| Angioplasty, Balloon | 1 | 2005 | 95 | 0.020 |
Why?
|
| Genetics, Population | 1 | 2007 | 394 | 0.020 |
Why?
|
| Laminectomy | 1 | 1984 | 27 | 0.020 |
Why?
|
| Debridement | 1 | 1984 | 56 | 0.020 |
Why?
|
| Analgesics, Opioid | 1 | 2008 | 413 | 0.010 |
Why?
|
| Spinal Fusion | 1 | 1984 | 85 | 0.010 |
Why?
|
| Codon | 1 | 2003 | 124 | 0.010 |
Why?
|
| Research Support as Topic | 1 | 2003 | 80 | 0.010 |
Why?
|
| Pituitary Irradiation | 1 | 1982 | 2 | 0.010 |
Why?
|
| Acromegaly | 1 | 1982 | 5 | 0.010 |
Why?
|
| Bias | 1 | 2003 | 127 | 0.010 |
Why?
|
| Computers | 1 | 1982 | 112 | 0.010 |
Why?
|
| Yttrium Radioisotopes | 1 | 1982 | 46 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 2003 | 399 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 1982 | 220 | 0.010 |
Why?
|
| Netherlands | 1 | 2001 | 19 | 0.010 |
Why?
|
| Evoked Potentials | 2 | 1993 | 190 | 0.010 |
Why?
|
| Minnesota | 1 | 2001 | 46 | 0.010 |
Why?
|
| Infant, Newborn | 2 | 1999 | 2379 | 0.010 |
Why?
|
| Brachytherapy | 1 | 1982 | 119 | 0.010 |
Why?
|
| Hemiplegia | 2 | 1991 | 15 | 0.010 |
Why?
|
| Sella Turcica | 1 | 2000 | 17 | 0.010 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2000 | 28 | 0.010 |
Why?
|
| Blood Pressure Determination | 1 | 2001 | 90 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2001 | 173 | 0.010 |
Why?
|
| Myelography | 1 | 2000 | 11 | 0.010 |
Why?
|
| Age Distribution | 1 | 2001 | 204 | 0.010 |
Why?
|
| Hemosiderin | 1 | 2000 | 2 | 0.010 |
Why?
|
| Hernia | 1 | 2000 | 23 | 0.010 |
Why?
|
| Educational Status | 1 | 2001 | 188 | 0.010 |
Why?
|
| Intracranial Thrombosis | 1 | 2000 | 27 | 0.010 |
Why?
|
| Names | 1 | 1999 | 10 | 0.010 |
Why?
|
| Verbal Behavior | 1 | 1999 | 32 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 2000 | 503 | 0.010 |
Why?
|
| Multifactorial Inheritance | 1 | 2001 | 159 | 0.010 |
Why?
|
| Speech | 1 | 1999 | 84 | 0.010 |
Why?
|
| Lod Score | 1 | 1998 | 152 | 0.010 |
Why?
|
| Neoplasm, Residual | 1 | 1999 | 162 | 0.010 |
Why?
|
| Calcinosis | 1 | 2000 | 224 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2000 | 454 | 0.010 |
Why?
|
| Ulcer | 1 | 1996 | 36 | 0.010 |
Why?
|
| Aneurysm, Infected | 1 | 1996 | 12 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 1996 | 56 | 0.010 |
Why?
|
| Lymphokines | 1 | 1996 | 76 | 0.010 |
Why?
|
| Biopsy | 1 | 2000 | 1163 | 0.010 |
Why?
|
| Mass Screening | 1 | 2000 | 618 | 0.010 |
Why?
|
| Elastin | 1 | 1995 | 7 | 0.010 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 1 | 1995 | 18 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 1996 | 160 | 0.010 |
Why?
|
| Time | 1 | 1995 | 77 | 0.010 |
Why?
|
| Molecular Probes | 1 | 1995 | 35 | 0.010 |
Why?
|
| Basement Membrane | 1 | 1995 | 54 | 0.010 |
Why?
|
| Extracellular Matrix | 1 | 1996 | 232 | 0.010 |
Why?
|
| Hemangioma, Capillary | 1 | 1993 | 7 | 0.010 |
Why?
|
| Videotape Recording | 1 | 1993 | 47 | 0.010 |
Why?
|
| Capillaries | 1 | 1993 | 91 | 0.010 |
Why?
|
| Sclerosis | 1 | 1992 | 28 | 0.010 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 1993 | 138 | 0.010 |
Why?
|
| Wechsler Scales | 1 | 1991 | 21 | 0.010 |
Why?
|
| Life Tables | 1 | 1991 | 48 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 1995 | 728 | 0.010 |
Why?
|
| Membrane Potentials | 1 | 1992 | 435 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 1992 | 989 | 0.010 |
Why?
|
| Spinal Cord Injuries | 1 | 1991 | 54 | 0.010 |
Why?
|
| Blood Flow Velocity | 1 | 1990 | 197 | 0.010 |
Why?
|
| Synapses | 1 | 1992 | 265 | 0.010 |
Why?
|
| Aphasia | 1 | 1989 | 14 | 0.010 |
Why?
|
| Remission Induction | 1 | 1991 | 722 | 0.010 |
Why?
|
| Ultrasonography | 1 | 1991 | 695 | 0.010 |
Why?
|
| Action Potentials | 1 | 1992 | 573 | 0.010 |
Why?
|
| Neurons | 1 | 1992 | 1546 | 0.000 |
Why?
|